Supplementary Table 1: Comparison of preoperative and postoperative CMRI results in primary MR patents undergoing MVR surgery. CMRI was performed on N=19 patients undergoing MVR surgery before (T0) and 6 months after (T1) procedure. Data are presented as mean \pm SD. Statistical significance of the differences between T0 and T1 was evaluated by paired Student's T test or Wilcoxon test depending on data distribution.

	TO	T1		p-value
LVEDVi [mL/m ²]	113.67 ± 25.37	73.52 ± 12.83	▼	1.90·10 ⁻⁶
LVESVi [mL/m ²]	42.50 ± 11.77	35.51 ± 9.56	▼	0.0055
RVEDVi [mL/m ²]	84.78 ± 15.57	66.92 ± 10.92	▼	1.30·10 ⁻⁵
RVESVi [mL/m ²]	34.44 ± 9.00	30.21 ± 7.50	▼	0.0352
LV Mass index [g/m ²]	77.44 ± 13.36	70.55 ± 10.02	▼	0.0035
LVSV [mL]	142.33 ± 35.93	74.84 ± 16.74	▼	7.14·10 ⁻⁷
LVSVi [mL/m ²]	72.36 ± 16.98	38.02 ± 7.64	▼	7.26·10 ⁻⁷
RVSV [mL]	100.67 ± 20.93	72.32 ± 16.80	▼	3.10 ·10 ⁻⁵
RVSVi [mL/m ²]	51.15 ± 9.72	36.71 ± 7.57	▼	3.70 ·10 ⁻⁵
LVEF [%]	62.60 ± 5.87	52.01 ± 7.82	▼	2.80 ·10 ⁻⁷
RVEF [%]	59.64 ± 6.56	54.89 ± 7.76	▼	0.0215
Heart rate [BPM]	61.00 ± 7.92	70.47 ± 12.89		0.0100
Cardiac index [mL/min ·m ²]	4180.36 ± 1114.27	2638.26 ± 555.51	▼	7.40·10 ⁻⁵
LA Area index [cm]	19.37 ± 7.89	9.95 ± 2.17	▼	7.60·10 ⁻⁶
RA Area [cm]	14.32 ± 5.71	10.58 ± 2.32	▼	0.0010
LA-max volume index [mL/m ²]	77.53 ± 27.15	37.77 ± 7.47	▼	1.30·10 ⁻⁵
LAEF [%]	53.44 ± 9.48	37.37 ± 10.83	▼	0.00067

Supplementary Table 2: Analysis of CMRI parameters in MR patients showing different rates of reverse remodeling after MVR surgery. CMRI data were collected for N=19 patients undergoing MVR surgery before (T0) and 6 months after (T1) the procedure. For each CMRI parameter measured, percentage change between T0 and T1 was computed as $\%\Delta = (T1-T0) / T0 * 100$ for each patient. T0, T1 and percentage change CMRI data ($\%\Delta$) were compared between LoR-REM and HiR-REM patients. Data are presented as mean \pm SD. Statistical significance of the differences was evaluated by independent samples Student's T test (with or without Welch's correction) or Mann Whitney test depending on data distribution.

1 0		LoR-REV	HiR-REV		p-value
	T0 [mL/m ²]	100.05 ± 13.34	125.93 ± 27.87		0.0209
LVEDVi	T1 [mL/m ²]	79.11 ± 8.67	68.50 ± 14.27	Ns	0.1774
	Δ(T1-T0)/ T0 [%]	-20.23 ± 9.86	-44.61 ± 9.94	▼	5.20·10 ⁻⁵
	T0 [mL/m ²]	39.82 ± 11.69	44.92 ± 11.92	Ns	0.3582
LVESVi	T1 [mL/m ²]	39.67 ± 9.45	31.90 ± 8.46	Ns	0.0758
	Δ(T1-T0)/ T0 [%]	$\textbf{2.40} \pm \textbf{21.87}$	-28.40 ± 10.97	▼	0.0010
	T0 [mL/m ²]	83.97 ± 13.40	85.52 ± 18.01	Ns	0.8340
RVEDVi	T1 [mL/m ²]	70.00 ± 8.66	64.10 ± 12.35	Ns	0.2496
	Δ(T1-T0)/ T0 [%]	-15.43 ± 12.70	-23.82 ± 12.44	Ns	0.1642
	T0 [mL/m ²]	34.67 ± 9.29	34.24 ± 9.24	Ns	0.9213
RVESVi	T1 [mL/m ²]	31.67 ± 8.03	28.90 ± 7.16	Ns	0.3234
	Δ(T1-T0)/ T0 [%]	-5.419 ± 25.49	-12.10 ± 22.84	Ns	0.5546
	T0 [g/m ²]	74.56 ± 7.57	80.04 ± 17.04	Ns	0.3727
LV Mass index	T1 [g/m ²]	72.94 ± 6.99	68.40 ± 12.09	Ns	0.3373
	Δ(T1-T0)/ T0 [%]	-1.928 ± 6.47	-13.43 ± 9.511	▼	0.0073
	T0 [mL/m ²]	60.26 ± 6.32	84.46 ± 15.60	A	0.0013
LVSVi	T1 [mL/m ²]	39.56 ± 7.21	36.60 ± 8.11	Ns	0.3030
	Δ(T1-T0)/ T0 [%]	-34.53 ± 9.70	-52.95 ± 12.70	▼	0.0032
	T0 [mL/m ²]	49.33 ± 7.11	52.98 ± 11.94	Ns	0.4423
RVSVi	T1 [mL/m ²]	38.33 ± 5.70	35.30 ± 8.98	Ns	0.3981
	Δ(T1-T0)/ T0 [%]	-21.24 ± 14.72	$\textbf{-28.37} \pm \textbf{14.31}$	Ns	0.3133
	T0 [%]	60.73 ± 7.21	64.28 ± 4.01	Ns	0.2114
LVEF	T1 [%]	50.33 ± 9.14	53.50 ± 6.29	Ns	0.3870
	Δ (T1-T0)/ T0 [%]	-17.64 ± 9.94	-16.50 ± 9.64	Ns	0.8030
	T0 [%]	59.12 ± 6.37	60.10 ± 7.02	Ns	0.7793
RVEF	T1 [%]	54.89 ± 8.42	54.70 ± 7.39	Ns	0.9591
	Δ(T1-T0)/ T0 [%]	-6.420 ± 13.19	-8.296 ± 12.63	Ns	0.7554
	T0 [BPM]	62.67 ± 9.26	59.50 ± 6.64	Ns	0.3998
Heart rate	T1 [BPM]	67.11 ± 14.22	73.50 ± 11.46	Ns	0.2937
	Δ(T1-T0)/ T0 [%]	8.353 ± 23.14	24.71 ± 22.66	Ns	0.1382
	T0 $[mL/min \cdot m^2]$	$3,\!498.15\pm703.51$	$4,\!794.35 \pm 1,\!076.56$		0.0070
Cardiac index	T1 [mL/min ·m ²]	2582 ± 397.3	2689 ± 686.2	Ns	0.6874
	Δ(T1-T0)/ T0 [%]	-20.93 ± 33.02	-41.55 ± 17.17	Ns	0.1128
	T0 [cm]	18.89 ± 7.20	19.80 ± 8.83	Ns	0.9483
LA Area	T1 [cm]	10.56 ± 2.55	9.40 ± 1.71	Ns	0.3352
	Δ(T1-T0)/ T0 [%]	-38.80 ± 21.70	-47.26 ± 14.97	Ns	0,3325
	T0 [cm]	17.11 ± 7.17	11.80 ± 2.15	Ns	0.0602
RA Area	T1 [cm]	11.33 ± 2.12	9.90 ± 2.38	Ns	0.1855
	Δ(T1-T0)/ T0 [%]	-25.65 ± 23.03	-15.33 ± 17.95	Ns	0.2885
	T0 [mL/m ²]	62.67 ± 12.33	89.09 ± 30.41		0.0371
LA-max volume index	T1 [mL/m ²]	38.01 ± 5.03	37.55 ± 9.44	Ns	0.8981
	Δ (Τ1-Τ0)/ ΤΟ [%]	-34.97 ± 15.45	-53.12 ± 11.58	▼	0.0175
	T0 [%]	52.29 ± 6.07	54.33 ± 11.78	Ns	0.8980
LAEF	T1 [%]	37.44 ± 10.47	37.30 ± 11.71	Ns	0.9778
	Δ(T1-T0)/ T0 [%]	-27.03 ± 20.15	$\textbf{-28.07} \pm \textbf{24.50}$	Ns	0.9291

Supplementary Table 3: Analysis of pEXO and exosomal miRNA in MR patients showing different rates of reverse remodeling after MVR surgery. pEXO were isolated from MR patients' (N=19) plasma collected before (T0) and 6 months after surgery (T1); N=8 healthy controls were also employed. pEXO were quantified by NTA as described in the methods. Exosomal miRNA-1, miRNA-21 and miRNA-133a were amplified and measured by qRT-PCR as described in the methods. Presurgical (T0) and postsurgical (T1) levels, and percentage perioperative change [(T1-T0)/T0 *100] were compared between LoR-REM and HiR-REM patients. Data are presented as median with interquartile range. Statistical significance of the differences between patients' groups was evaluated by independent samples Student's T test (with or without Welch's correction) or Mann Whitney test depending on data distribution. Statistical differences between patients and controls was evaluated by one-way ANOVA (with or without Brown-Forsythe modification for heteroscedastic groups) or Kruskal-Wallis test, depending on sample distribution; p'= p-value LOW-Rev-Rem vs Controls; p''=p-value HIGH-Rev-rem vs Controls.

		LoR-REV	HiR-REV	p-value	Controls	p'	р"
pEXO	T0 [particles/mL]	1.36·10 ⁹ (7.99·10 ⁸ - 1.99·10 ⁹)	1.48·10 ⁹ (6.92·10 ⁸ - 2.89·10 ⁹)	0.6607	$\frac{1.08 \cdot 10^9}{(8.78 \cdot 10^8 - 1.39 \cdot 10^9)}$	0.8522	0.5013
	T1 [particles/mL]	$\frac{1.31 \cdot 10^9}{(7.52 \cdot 10^8 - 1.57 \cdot 10^9)}$	1.89·10 ⁹ (1.43·10 ⁸ - 2.49·10 ⁹)	0.0625	$\frac{1.08 \cdot 10^9}{(8.78 \cdot 10^8 - 1.39 \cdot 10^9)}$	>0.9999	0.0159
	Δ(T1-T0)/ T0 [%]	-4.62 (-56.76 - 137.24)	26.03 (-12.46 - 206.38)	0.4470			
miR-1	ТО [2-ДАСТ]	1.137 (0.339 - 1.838)	1.405 (1.058 - 2.732)	0.2428	0.771 (0.312 - 2.431)	>0.9999	0.2685
	T1 [2-ΔΔCT]	0.313 (0.0034 – 1.105)	1.184 (0.594 - 2.386)	0.0179	0.771 (0.312 - 2.431)	0.1795	0.8747
	Δ(T1-T0)/ T0 [%]	-75.52 (-99.17 - 13.52)	-27.78 (-66.94 - 100.73)	0.1487			
miR-21	ТО [2-ааст]	1.993 (0.946 - 6.285)	2.485 (1.274 - 8.530)	0.7209	1.053 (0.419 - 2.081)	0.4062	0.5777
	T1 [2-ΔΔCT]	2.289 (0.777 – 6.101)	9.314 (1.512 - 13.081)	0.0303	1.053 (0.419 - 2.081)	0.4749	0.0251
	Δ(T1-T0)/ T0 [%]	14.87 (-32.90 - 52.75)	56.49 (-40.64 - 386.57)	0.2973			
miR-133a	ТО [2-ааст]	0.772 (0.364 - 2.110)	0.962 (0.521 - 1.925)	0.3562	1.205 (0.418 - 2.536)	0.7094	>0.9999
	T1 [2-ΔΔCT]	0.456 (0.3657 – 1.081)	1.835 (0.5974 - 3.964)	0.0464	1.205 (0.418 - 2.536)	0.2882	>0.9999
	Δ(T1-T0)/ T0 [%]	-13.31 (-55.74 - 46.80)	11.26 (-36.49 - 179.10)	0.2107			

Supplementary Table 4: Analysis of CMRI parameters in MR patients with upregulated or downregulated postoperative levels of pEXO. CMRI and pEXO data were collected from MR patients (N=19) before (T0) and 6 months after MVR surgery (T1); isolated pEXO were quantified by NTA as described in the methods. Percentage of change in pEXO was calculated as $\%\Delta = (T1-T0)/T0 * 100$, and patients were grouped depending on exosome decrease (DOWN, $\%\Delta <0$) or increase (UP, $\%\Delta >0$) after surgery. Percentage variation of CMRI parameters between the presurgical scan (T0) and the postsurgical follow up (T1) was calculated as $\%\Delta = (T1-T0)/T0 * 100$. T0, T1 and percentage change CMRI data ($\%\Delta$) were compared between patients with exosome downregulation (DOWN) and patients with exosome increase (UP) after surgery. Data are presented as mean \pm SD. Statistical significance of the differences was evaluated by independent samples Student's T test (with or without Welch's correction) or Mann Whitney test depending on data distribution.

		Decrease in exosome secretion (DOWN)	Increase in exosome secretion (UP)		p-value
	T0 [mL/m ²]	116.7 ± 27.07	111.9 ± 25.38	Ns	0.6995
LVEDVi	T1 [mL/m ²]	79.57 ± 6.60	70.00 ± 14.46	Ns	0.1195
	Δ(T1-T0)/ T0 [%]	-30.02 ± 9.42	$\textbf{-34.84} \pm \textbf{18.71}$	Ns	0.5367
	T0 [mL/m ²]	46.43 ± 14.98	40.21 ± 9.45	Ns	0.2794
LVESVi	T1 [mL/m ²]	39.57 ± 8.32	33.25 ± 9.78	Ns	0.1707
	Δ(T1-T0)/ T0 [%]	-11.91 ± 13.56	-14.92 ± 27.41	Ns	0.5358
	T0 [mL/m ²]	85.91 ± 13.50	84.12 ± 17.20	Ns	0.8160
RVEDVi	T1 [mL/m ²]	69.00 ± 7.85	65.67 ± 12.50	Ns	0.5356
	Δ(T1-T0)/ T0 [%]	-18.38 ± 12.46	-20.70 ± 13.69	Ns	0.7171
	T0 [mL/m ²]	34.89 ± 7.935	34.18 ± 9.90	Ns	0.8751
RVESVi	T1 [mL/m ²]	28.43 ± 7.57	31.25 ± 7.59	Ns	0.4449
	Δ(T1-T0)/ T0 [%]	-16.34 ± 20.68	-4.62 ± 25.10	Ns	0.3116
	T0 [g/m ²]	78.10 ± 14.00	77.05 ± 13.59	Ns	0.8742
LV Mass index	T1 [g/m ²]	76.16 ± 10.20	67.28 ± 8.69	Ns	0.0598
	Δ(T1-T0)/ T0 [%]	-1.75 ± 7.10	-11.62 ± 9.74	▼	0.0323
	T0 [mL/m ²]	70.29 ± 16.49	73.73 ± 17.99	Ns	0.6886
LVSVi	T1 [mL/m ²]	40.14 ± 8.82	36.75 ± 6.96	Ns	0.4030
	Δ(T1-T0)/ T0 [%]	-41.93 ± 12.58	$\textbf{-44.90} \pm \textbf{16.08}$	Ns	0.6856
	T0 [mL/m ²]	51.00 ± 8.00	51.18 ± 11.16	Ns	0.9707
RVSVi	T1 [mL/m ²]	40.57 ± 5.25	34.50 ± 7.98	Ns	0.0916
	Δ(T1-T0)/ T0 [%]	-19.93 ± 9.91	-27.90 ± 16.55	Ns	0.2698
	T0 [%]	60.57 ± 7.57	63.75 ± 4.53	Ns	0.2644
LVEF	T1 [%]	50.57 ± 10.29	52.83 ± 6.13	Ns	0.5530
	Δ(T1-T0)/ T0 [%]	-17.11 ± 11.57	-16.99 ± 8.69	Ns	0.9806
	T0 [%]	59.71 ± 5.85	59.50 ± 7.28	Ns	0.9480
RVEF	T1 [%]	58.86 ± 7.71	52.42 ± 6.87	Ns	0.0764
	Δ(T1-T0)/ T0 [%]	-1.03 ± 8.88	-11.13 ± 13.21	Ns	0.0911
	T0 [BPM]	60.00 ± 6.63	61.58 ± 8.82	Ns	0.6867
Heart rate	T1 [BPM]	66.86 ± 15.51	72.58 ± 11.30	Ns	0.3653
	Δ(T1-T0)/ T0 [%]	10.83 ± 17.73	20.54 ± 26.75	Ns	0.4062
	T0 [mL/min ·m ²]	4176 ± 791.3	4183 ± 1300	Ns	0.9907
Cardiac index	T1 [mL/min ·m ²]	2581 ± 330.0	2671 ± 665.0	Ns	0.7435
	Δ(T1-T0)/ T0 [%]	-37.29 ± 7.73	-28.57 ± 33.97	Ns	0.4097
	T0 [cm]	19.29 ± 7.16	19.42 ± 8.60	Ns	0.8857
LA Area	T1 [cm]	9.714 ± 1.70	10.08 ± 2.47	Ns	0.9056
	Δ(T1-T0)/ T0 [%]	-45.04 ± 18.51	-42.21 ± 19.15	Ns	0.7565
	T0 [cm]	16.29 ± 7.87	13.17 ± 3.95	Ns	0.6939
RA Area	T1 [cm]	11.14 ± 2.48	10.25 ± 2.26	Ns	0.4335
	Δ(T1-T0)/ T0 [%]	-23.22 ± 20.78	-18.47 ± 21.23	Ns	0.6413
	T0 [mL/m ²]	74.18 ± 13.39	79.55 ± 33.42	Ns	0.7156
LA-max volume index	T1 [mL/m ²]	40.22 ± 6.51	36.34 ± 7.88	Ns	0.2867
	Δ(T1-T0)/ Τ0 [%]	-43.03 ± 8.86	-46.48 ± 19.34	Ns	0.6895
	T0 [%]	48.83 ± 3.54	56.20 ± 10.96	Ns	0.0740
LAEF	T1 [%]	34.86 ± 10.29	38.83 ± 11.30	Ns	0.4559
	Δ(T1-T0)/ T0 [%]	-24.50 ± 18.48	-29.48 ± 24.59	Ns	0.6765



Supplementary Figure 1: Analysis of preoperative (T0) and postoperative (T1) CMRI parameters in MR patients showing different rates of reverse remodeling after MVR surgery. CMRI data were collected for N=19 patients undergoing MVR surgery before (T0) and 6 months after (T1) the procedure. Data were compared between LoR-REM and HiR-REM patients. Individual data are shown, horizontal bars represent group average. Statistical significance of the differences was evaluated by independent samples Student's T test (with or without Welch's correction) or Mann Whitney test depending on data distribution. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.001.



Supplementary Figure 2: Analysis of CMRI parameters in MR patients with upregulated or downregulated postoperative levels of pEXO. CMRI and pEXO data were collected from MR patients (N=19) before (T0) and 6 months after MVR surgery (T1); isolated pEXO were quantified by NTA as described in the methods. Percentage of change in pEXO was calculated as $\%\Delta = (T1-T0)/T0 * 100$, and patients were grouped depending on exosome decrease (DOWN, $\%\Delta <0$) or increase (UP, $\%\Delta >0$) after surgery. Percentage variation of CMRI parameters between the presurgical scan (T0) and the postsurgical follow up (T1) was calculated as $\%\Delta = (T1-T0)/T0 * 100$. Data are compared between patients with exosome downregulation (DOWN) and patients with exosome increase (UP) after surgery. Individual data are shown; horizontal bars represent group average. Statistical significance of the differences was evaluated by independent samples Student's T test (with or without Welch's correction) or Mann Whitney test depending on data distribution. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.



Supplementary figure 3: Effect of pEXOs from patients with different grade of reverse ventricular remodeling on cardiomyocytes size. HL-1 cells were seeded at a concentration of 5,000 cells / cm² and allowed to adhere for 24 h before treatment. Cells were treated with $\pm 1 \mu$ M Angiotensin II (AngII, Sigma) in complete Claycomb medium for 48 hours. A PBS suspension of pEXOs isolated from HiR- or LoR-REM group at T1 was added to a final concentration of $1 \cdot 10^9$ particles / mL, 24 h after the beginning of the treatment, and the treatment was maintained for the remaining 24 h; PBS was employed as a control. RNA was isolated using using PRImeZOLTM reagent and RT-PCR performed as described in the methods. Relative expression of specific markers is presented in the figure: A) ANP; B)BNP; C) β -MHC (MYH7) D) SERCA2a.